- Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance Expect Phase 2 data from VIBRANT in Q4 2021
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021 newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.